A 62-year-old male with COPD and chronic sputum production is hospitalized with ventilator-associated pneumonia (VAP). Sputum culture grows Pseudomonas aeruginosa. All of the following are correct regarding P. aeruginosa antibiotic resistance mechanisms EXCEPT:

Explanation

## Antibiotic Resistance Mechanisms in Pseudomonas aeruginosa ### Correct Resistance Mechanisms (Options A, B, D) **Key Point:** P. aeruginosa is intrinsically resistant to many antibiotics and readily acquires additional resistance through chromosomal and plasmid-mediated mechanisms. This is a major clinical challenge in VAP and chronic respiratory infections. | Mechanism | Antibiotic Class Affected | Prevalence | Clinical Significance | | --- | --- | --- | --- | | Efflux pumps (MexAB-OprM, others) | Fluoroquinolones, β-lactams, macrolides | Very common | Multi-drug efflux; often combined with other mechanisms | | Altered PBPs | Carbapenems, β-lactams | Moderate | Reduces carbapenem efficacy; often seen in MDR strains | | Aminoglycoside-modifying enzymes | Aminoglycosides | Common | Phosphorylation, adenylylation, acetylation of drug | | 16S rRNA methylation (RmtA, RmtB, RmtD) | Aminoglycosides | Rare but documented | High-level, pan-aminoglycoside resistance in some P. aeruginosa strains | ### Why ESBL Production is the INCORRECT Statement (Option C) **High-Yield:** ESBLs (Extended-Spectrum β-Lactamases) are classically associated with **Enterobacteriaceae** (e.g., *Klebsiella pneumoniae*, *E. coli*) and are NOT the primary or characteristic β-lactamase resistance mechanism in *P. aeruginosa*. The dominant β-lactam resistance mechanisms in *P. aeruginosa* are: 1. **AmpC β-lactamase overexpression** (chromosomally encoded, inducible/derepressed) — this is the hallmark mechanism that inactivates third-generation cephalosporins 2. **Efflux pumps** (MexAB-OprM, MexCD-OprJ, MexXY-OprM) 3. **Porin loss** (OprD downregulation) — particularly relevant for carbapenem resistance 4. **Metallo-β-lactamases** (e.g., VIM, IMP) — carbapenemases, not ESBLs **Clinical Pearl:** While rare ESBL-producing *P. aeruginosa* strains have been reported in the literature, ESBL production is **not** a recognized or standard resistance mechanism for this organism. Attributing third-generation cephalosporin resistance in *P. aeruginosa* to ESBL production is factually incorrect in standard teaching (Mandell's Principles of Infectious Diseases; Murray's Medical Microbiology). The correct mechanism for cephalosporin resistance in *P. aeruginosa* is AmpC overexpression. **Regarding Option D:** 16S rRNA methylation (mediated by RmtA, RmtB, RmtC, RmtD methylases) **does** occur in *P. aeruginosa* — it is rare but well-documented and confers high-level, broad-spectrum aminoglycoside resistance. Therefore, Option D is a **correct** statement about *P. aeruginosa* resistance mechanisms and is NOT the exception. **Mnemonic:** **PEAM** for P. aeruginosa resistance — **P**umps (efflux), **E**nzymes (AmpC, aminoglycoside-modifying), **A**ltered PBPs, **M**utations (OprD porin loss, regulatory genes). **Reference:** Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed.; Murray's Medical Microbiology, 9th ed.